SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divi's Laboratories surges on inking supply agreement with global pharmaceuticals firm

21 Apr 2025 Evaluate

Divi's Laboratories is currently trading at Rs 5815.00, up by 176.65 points or 3.13% from its previous closing of Rs 5638.35 on the BSE.

The scrip opened at Rs 5869.70 and has touched a high and low of Rs 5905.00 and Rs 5798.70 respectively. So far 10370 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52-week high of Rs 6448.75 on 02-Dec-2024 and a 52-week low of Rs 3640.10 on 19-Apr-2024.

Last one week high and low of the scrip stood at Rs 5905.00 and Rs 5592.70 respectively. The current market cap of the company is Rs 154369.98 crore.

The promoters holding in the company stood at 51.89%, while Institutions and Non-Institutions held 38.72% and 9.39% respectively.

Divi's Laboratories has inked a supply agreement with a global pharmaceuticals firm. Under the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The company expects meaningful revenue contribution from this long-term agreement.

The company is planning for capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals.

Divi's Laboratories is one of the leading pharmaceutical companies in the world.

Divis Lab Share Price

6228.95 -68.55 (-1.09%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×